| Item type |
文献 / Documents(1) |
| 公開日 |
2018-04-27 |
| アクセス権 |
|
|
アクセス権 |
open access |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版社版DOI |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.2152/jmi.65.90 |
|
|
言語 |
ja |
|
|
関連名称 |
10.2152/jmi.65.90 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| タイトル |
|
|
タイトル |
A feasibility study of postoperative adjuvant chemotherapy with fluoropyrimidine S-1 in patients with stage II-IIIA non-small cell lung cancer |
|
言語 |
en |
| 著者 |
坪井, 光弘
近藤, 和也
滝沢, 宏光
河北, 直也
澤田, 徹
鳥羽, 博明
川上, 行奎
吉田, 光輝
イシクラ, ヒサシ
キムラ, スグル
丹黒, 章
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background : Adjuvant chemotherapy with uracil tegafur (UFT) improved survival among patients with completely resected stage I lung adenocarcinoma. S-1, an oral dihydropyrimidine dehydrogenase (DPD)- inhibitory 5-fluorouracil, is a more potent DPD inhibitor than UFT ; therefore, we hypothesized that postoperative adjuvant chemotherapy with S-1 would be effective for advanced non-small cell lung cancer (NSCLC). We conducted a feasibility study of S-1 as postoperative adjuvant chemotherapy in patients with curatively resected pathological stage II and IIIA NSCLC. Methods : Adjuvant chemotherapy consisted of 9 courses (4-week administration, 2-week withdrawal) of S-1 at 80-120 mg/body per day. Twenty-four patients with completely resected NSCLC were enrolled in this study from November 2007 through December 2010. The primary endpoint was the rate of completion of the scheduled adjuvant chemotherapy. The secondary endpoints were safety, overall survival, and relapse-free survival. Results : Five patients were censored because of disease recurrence. The planned 9 courses of S-1 were administered to completion in 8 patients. Twelve patients completed more than 70% of the planned courses. Grade 3 adverse reactions, such as elevated total bilirubin (4.2%) and pneumonitis (4.2%), were observed, but there were no Grade 4 adverse reactions. Patients who completed more than 70% of the 9 courses demonstrated better overall survival than those who completed less than 70%. Conclusion : Postoperative administration of S-1 may be possible with few severe adverse events as adjuvant chemotherapy for patients with curatively resected pathological stage II-IIIA NSCLC. |
|
言語 |
en |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Non-small cell lung cancer |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
S-1 |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
adjuvant chemotherapy |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
feasibility study |
| 書誌情報 |
en : The Journal of Medical Investigation
巻 65,
号 1-2,
p. 90-95,
発行日 2018-02
|
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
13496867 |
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
13431420 |
| 収録物ID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA11166929 |
| 収録物ID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA12022913 |
| 出版者 |
|
|
出版者 |
Faculty of Medicine Tokushima University |
|
言語 |
en |
| EID |
|
|
識別子 |
349323 |
|
識別子タイプ |
URI |
| 言語 |
|
|
言語 |
eng |
jmi_65_1-2_90.pdf (628 KB)
